Detailed price information for Vanda Pharmaceuticals (VNDA-Q) from The Globe and Mail including charting and trades.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company,' 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...

An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Detailed price information for Maia Biotechnology Inc (MAIA-A) from The Globe and Mail including charting and trades.

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...